{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:57:22Z","timestamp":1781067442297,"version":"3.54.1"},"reference-count":144,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Parkinson\u2019s Disease (PD) is a neurological disease marked by the buildup of \u03b1-synuclein.\nThe main symptom of the disease is the degeneration of dopaminergic neurons in the substantia\nnigra pars compacta (SNc). Gene therapy may be a treatment option for PD and has been used in\nclinical trials to treat a variety of illnesses in the human brain. Currently, the majority of gene therapy\nclinical studies are being conducted to treat PD. The primary objective is to enhance medications\nthat address motor issues. Patients with PD have been the subjects of several gene therapy treatment\ntechniques that have been developed and tested. Genes are typically transported to neurons in brain\nregions relevant to PD, such as the striatum, using viral vectors. It may only be necessary to administer\nthese gene delivery methods once, and they may induce expression to persist for an extended\ntime. Several neurotrophic factors, including neurturin, GDNF, BDNF, CDNF, and VEGF-A, have\ndemonstrated promising outcomes in preclinical models as potential disease-modifying targets that\nmay slow disease development. Currently available treatment regimens for PD mostly comprise the\nadministration of levodopa (L-DOPA), dopamine agonists or MAO-B inhibitors, or surgery in the\nform of deep brain stimulation or neuroablative surgery, among other options. Many different targeting\nmoieties for PD treatment, as well as current treatment techniques and gene therapy methodologies,\nare covered in this review article. The research reviewed the relevant literature on the potential\nrole of gene therapy for the treatment of PD. The research articles are obtained through various\ndatabases, including ScienceDirect, Scopus, PubMed, and Google Scholar. This review includes\nvarious targeting moieties for the treatment of PD, current PD treatment strategies, PD treatment\nusing gene therapy, comparison of risk-benefit ratios of gene therapy vs. DBS\/drugs, and gene vector\ntechnology in the treatment of PD. This review compiles data on Parkinson's disease, its current\ntreatment strategies, and the potential role of gene therapy in its treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113895575405524251008112752","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T04:06:31Z","timestamp":1762401991000},"page":"332-352","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancement in Gene Therapy for the Treatment of Parkinson\u2019s Disease: A Comprehensive Review"],"prefix":"10.2174","volume":"26","author":[{"given":"Mitul","family":"Lovras","sequence":"first","affiliation":[{"name":"IITM College of Pharmacy, Murthal, Sonipat, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Rana","sequence":"additional","affiliation":[{"name":"Hindu College of Pharmacy, Gohana Road, Sonipat, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam","family":"Rani","sequence":"additional","affiliation":[{"name":"Hindu College of Pharmacy, Gohana Road, Sonipat, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajesh","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Hindu College of Pharmacy, Gohana Road, Sonipat, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathvik Belagodu","family":"Sridhar","sequence":"additional","affiliation":[{"name":"RAK College of Pharmacy, RAK Medical &amp; Health Sciences University, Ras Al Khaimah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Rajput","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-6149","authenticated-orcid":true,"given":"Rishabha","family":"Malviya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Wadhwa","sequence":"additional","affiliation":[{"name":"RAK College of Pharmacy, RAK Medical &amp; Health Sciences University, Ras Al Khaimah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0002-9459(24)04585-6","volume":"60","author":"Smith T.J.","year":"1996","unstructured":"Smith T.J.; Gene therapy: Opportunities for pharmacy in the 21st century. Am J Pharm Educ  1996,60(2),213-215","journal-title":"Am J Pharm Educ"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"Dunbar C.E.","year":"2018","unstructured":"Dunbar C.E.; High K.A.; Joung J.K.; Kohn D.B.; Ozawa K.; Sadelain M.; Gene therapy comes of age. Science  2018,359(6372),eaan4672","journal-title":"Science"},{"key":"ref=3","first-page":"270","volume":"1","author":"Stoner N.","year":"2009","unstructured":"Stoner N.; Gene therapy applications. Clin Pharm  2009,1,270-273","journal-title":"Clin Pharm"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"106614","DOI":"10.1016\/j.cnsns.2022.106614","volume":"114","author":"Wang Z.","year":"2022","unstructured":"Wang Z.; Hu B.; Zhu L.; Lin J.; Xu M.; Wang D.; Hopf bifurcation analysis for Parkinson oscillation with heterogeneous delays: A theoretical derivation and simulation analysis. Commun Nonlinear Sci Numer Simul  2022,114,106614","journal-title":"Commun Nonlinear Sci Numer Simul"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"a008862","DOI":"10.1101\/cshperspect.a008862","volume":"1","author":"Goetz C.G.","year":"2011","unstructured":"Goetz C.G.; The history of Parkinson\u2019s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med  2011,1(1),a008862","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"Gibb W.R.","year":"1988","unstructured":"Gibb W.R.; Lees A.J.; The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry  1988,51(6),745-752","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/jnnp-2012-303455","volume":"84","author":"Marras C.","year":"2013","unstructured":"Marras C.; Lang A.; Parkinson\u2019s disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry  2013,84(4),409-415","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"116267","DOI":"10.1016\/j.chaos.2025.116267","volume":"195","author":"Hu B.","year":"2025","unstructured":"Hu B.; Wang X.; Lu S.; Ying X.; A study of bidirectional control of Parkinson\u2019s beta oscillations by basal ganglia. Chaos Solitons Fractals  2025,195,116267","journal-title":"Chaos Solitons Fractals"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"113022","DOI":"10.1016\/j.chaos.2022.113022","volume":"166","author":"Wang Z.","year":"2023","unstructured":"Wang Z.; Hu B.; Zhou W.; Xu M.; Wang D.; Hopf bifurcation mechanism analysis in an improved cortex-basal ganglia network with distributed delays: An application to Parkinson\u2019s disease. Chaos Solitons Fractals  2023,166,113022","journal-title":"Chaos Solitons Fractals"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/1566523052997505","volume":"5","author":"Chen Q.","year":"2005","unstructured":"Chen Q.; He Y.; Yang K.; Gene therapy for Parkinson\u2019s disease: progress and challenges. Curr Gene Ther  2005,5(1),71-80","journal-title":"Curr Gene Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00002512-199914040-00003","volume":"14","author":"Collier T.J.","year":"1999","unstructured":"Collier T.J.; Sortwell C.E.; Therapeutic potential of nerve growth factors in Parkinson\u2019s disease. Drugs Aging  1999,14(4),261-287","journal-title":"Drugs Aging"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn812","volume":"3","author":"Airaksinen M.S.","year":"2002","unstructured":"Airaksinen M.S.; Saarma M.; The GDNF family: Signalling, biological functions and therapeutic value. Nat Rev Neurosci  2002,3(5),383-394","journal-title":"Nat Rev Neurosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/NEN.0b013e31822830e5","volume":"70","author":"Lei Z.","year":"2011","unstructured":"Lei Z.; Jiang Y.; Li T.; Zhu J.; Zeng S.; Signaling of glial cell line-derived neurotrophic factor and its receptor GFR\u03b11 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease. J Neuropathol Exp Neurol  2011,70(9),736-747","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1126\/science.276.5310.248","volume":"276","author":"Zetterstr\u00f6m R.H.","year":"1997","unstructured":"Zetterstr\u00f6m R.H.; Solomin L.; Jansson L.; Hoffer B.J.; Olson L.; Perlmann T.; Dopamine neuron agenesis in Nurr1-deficient mice. Science  1997,276(5310),248-250","journal-title":"Science"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"Gill S.S.","year":"2003","unstructured":"Gill S.S.; Patel N.K.; Hotton G.R.; O\u2019Sullivan K.; McCarter R.; Bunnage M.; Brooks D.J.; Svendsen C.N.; Heywood P.; Direct brain infusion of glial cell line\u2013derived neurotrophic factor in Parkinson disease. Nat Med  2003,9(5),589-595","journal-title":"Nat Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","volume":"102","author":"Slevin J.T.","year":"2005","unstructured":"Slevin J.T.; Gerhardt G.A.; Smith C.D.; Gash D.M.; Kryscio R.; Young B.; Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line\u2014derived neurotrophic factor. J Neurosurg  2005,102(2),216-222","journal-title":"J Neurosurg"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/cne.10689","volume":"461","author":"Ai Y.","year":"2003","unstructured":"Ai Y.; Markesbery W.; Zhang Z.; Grondin R.; Elseberry D.; Gerhardt G.A.; Gash D.M.; Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects. J Comp Neurol  2003,461(2),250-261","journal-title":"J Comp Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0197-4580(02)00022-2","volume":"23","author":"Maswood N.","year":"2002","unstructured":"Maswood N.; Grondin R.; Zhang Z.; Stanford J.; Surgener S.; Gash D.; Gerhardt G.; Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging  2002,23(5),881-889","journal-title":"Neurobiol Aging"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/brain\/awf234","volume":"125","author":"Grondin R.","year":"2002","unstructured":"Grondin R.; Zhang Z.; Yi A.; Cass W.A.; Maswood N.; Andersen A.H.; Elsberry D.D.; Klein M.C.; Gerhardt G.A.; Gash D.M.; Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced Parkinsonian monkeys. Brain  2002,125(10),2191-2201","journal-title":"Brain"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.20374","volume":"57","author":"Patel N.K.","year":"2005","unstructured":"Patel N.K.; Bunnage M.; Plaha P.; Svendsen C.N.; Heywood P.; Gill S.S.; Intraputamenal infusion of glial cell line\u2013derived neurotrophic factor in PD: A two\u2010year outcome study. Ann Neurol  2005,57(2),298-302","journal-title":"Ann Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"Lang A.E.","year":"2006","unstructured":"Lang A.E.; Gill S.; Patel N.K.; Lozano A.; Nutt J.G.; Penn R.; Brooks D.J.; Hotton G.; Moro E.; Heywood P.; Brodsky M.A.; Burchiel K.; Kelly P.; Dalvi A.; Scott B.; Stacy M.; Turner D.; Wooten V.G.F.; Elias W.J.; Laws E.R.; Dhawan V.; Stoessl A.J.; Matcham J.; Coffey R.J.; Traub M.; Randomized controlled trial of intraputamenal glial cell line\u2013derived neurotrophic factor infusion in Parkinson disease. Ann Neurol  2006,59(3),459-466","journal-title":"Ann Neurol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1096\/fj.07-8797com","volume":"22","author":"Chen Y.H.","year":"2008","unstructured":"Chen Y.H.; Harvey B.K.; Hoffman A.F.; Wang Y.; Chiang Y.H.; Lupica C.R.; MPTP\u2010induced deficits in striatal synaptic plasticity are prevented by glial cell line\u2010derived neurotrophic factor expressed via an adeno\u2010associated viral vector. FASEB J  2008,22(1),261-275","journal-title":"FASEB J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.neulet.2007.05.033","volume":"421","author":"Tian Y.","year":"2007","unstructured":"Tian Y.; Tang C.J.; Wang J.; Feng Y.; Chen X.; Wang L.; Qiao X.; Sun S.; Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors. Neurosci Lett  2007,421(3),239-244","journal-title":"Neurosci Lett"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1089\/hum.2014.003","volume":"25","author":"Lu-Nguyen N.B.","year":"2014","unstructured":"Lu-Nguyen N.B.; Broadstock M.; Schliesser M.G.; Bartholomae C.C.; von Kalle C.; Schmidt M.; Y\u00e1\u00f1ez-Mu\u00f1oz R.J.; Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson\u2019s disease. Hum Gene Ther  2014,25(7),631-641","journal-title":"Hum Gene Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3727\/096368912X657693","volume":"22","author":"Sterky F.H.","year":"2013","unstructured":"Sterky F.H.; Pernold K.; Harvey B.K.; Lindqvist E.; Hoffer B.J.; Olson L.; Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons. Cell Transplant  2013,22(9),1529-1539","journal-title":"Cell Transplant"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.nano.2017.02.006","volume":"13","author":"Espadas-Alvarez A.J.","year":"2017","unstructured":"Espadas-Alvarez A.J.; Bannon M.J.; Orozco-Barrios C.E.; Escobedo-Sanchez L.; Ayala-Davila J.; Reyes-Corona D.; Soto-Rodriguez G.; Escamilla-Rivera V.; De Vizcaya-Ruiz A.; Eugenia Gutierrez-Castillo M.; Padilla-Viveros A.; Martinez-Fong D.; Regulation of human GDNF gene expression in nigral dopaminergic neurons using a new doxycycline-regulated NTS-polyplex nanoparticle system. Nanomedicine  2017,13(4),1363-1375","journal-title":"Nanomedicine"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jcjo.2024.01.018","volume":"59","author":"Rajput S.","year":"2024","unstructured":"Rajput S.; Malviya R.; Uniyal P.; Advancements in the diagnosis, prognosis, and treatment of retinoblastoma. Can J Ophthalmol  2024,59(5),281-299","journal-title":"Can J Ophthalmol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1089\/hum.2009.103","volume":"20","author":"Su X.","year":"2009","unstructured":"Su X.; Kells A.P.; Huang E.J.; Lee H.S.; Hadaczek P.; Beyer J.; Bringas J.; Pivirotto P.; Penticuff J.; Eberling J.; Federoff H.J.; Forsayeth J.; Bankiewicz K.S.; Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther  2009,20(12),1627-1640","journal-title":"Hum Gene Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/mt.2008.170","volume":"16","author":"Herzog C.D.","year":"2008","unstructured":"Herzog C.D.; Dass B.; Gasmi M.; Bakay R.; Stansell J.E.; Tuszynski M.; Bankiewicz K.; Chen E.Y.; Chu Y.; Bishop K.; Kordower J.H.; Bartus R.T.; Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther  2008,16(10),1737-1744","journal-title":"Mol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"Warren Olanow C.","year":"2015","unstructured":"Warren Olanow C.; Bartus R.T.; Baumann T.L.; Factor S.; Boulis N.; Stacy M.; Turner D.A.; Marks W.; Larson P.; Starr P.A.; Jankovic J.; Simpson R.; Watts R.; Guthrie B.; Poston K.; Henderson J.M.; Stern M.; Baltuch G.; Goetz C.G.; Herzog C.; Kordower J.H.; Alterman R.; Lozano A.M.; Lang A.E.; Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial. Ann Neurol  2015,78(2),248-257","journal-title":"Ann Neurol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","volume":"80","author":"Bartus R.T.","year":"2013","unstructured":"Bartus R.T.; Baumann T.L.; Siffert J.; Herzog C.D.; Alterman R.; Boulis N.; Turner D.A.; Stacy M.; Lang A.E.; Lozano A.M.; Olanow C.W.; Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology  2013,80(18),1698-1701","journal-title":"Neurology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JPD-181331","volume":"8","author":"Axelsen T.M.","year":"2018","unstructured":"Axelsen T.M.; Woldbye D.P.D.; Gene therapy for Parkinson\u2019s disease, an update. J Parkinsons Dis  2018,8(2),195-215","journal-title":"J Parkinsons Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0014-4886(88)90013-1","volume":"101","author":"Hagg T.","year":"1988","unstructured":"Hagg T.; Manthorpe M.; Vahlsing H.L.; Varon S.; Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage. Exp Neurol  1988,101(2),303-312","journal-title":"Exp Neurol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.21032","volume":"60","author":"Kordower J.H.","year":"2006","unstructured":"Kordower J.H.; Herzog C.D.; Dass B.; Bakay R.A.E.; Stansell J.; Gasmi M.; Bartus R.T.; Delivery of neurturin by AAV2 (CERE\u2010120)\u2010mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP\u2010treated monkeys. Ann Neurol  2006,60(6),706-715","journal-title":"Ann Neurol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/mds.21503","volume":"22","author":"Herzog C.D.","year":"2007","unstructured":"Herzog C.D.; Dass B.; Holden J.E.; Stansell J.; Gasmi M.; Tuszynski M.H.; Bartus R.T.; Kordower J.H.; Striatal delivery of CERE\u2010120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord  2007,22(8),1124-1132","journal-title":"Mov Disord"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"Marks W.J.","year":"2008","unstructured":"Marks W.J.; Ostrem J.L.; Verhagen L.; Starr P.A.; Larson P.S.; Bakay R.A.E.; Taylor R.; Cahn-Weiner D.A.; Stoessl A.J.; Olanow C.W.; Bartus R.T.; Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2\u2013neurturin) to patients with idiopathic Parkinson\u2019s disease: An open-label, phase I trial. Lancet Neurol  2008,7(5),400-408","journal-title":"Lancet Neurol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mds.23442","volume":"26","author":"Bartus R.T.","year":"2011","unstructured":"Bartus R.T.; Herzog C.D.; Chu Y.; Wilson A.; Brown L.; Siffert J.; Johnson E.M.; Olanow C.W.; Mufson E.J.; Kordower J.H.; Bioactivity of AAV2\u2010neurturin gene therapy (CERE\u2010120): Differences between Parkinson\u2019s disease and nonhuman primate brains. Mov Disord  2011,26(1),27-36","journal-title":"Mov Disord"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.nbd.2015.03.023","volume":"78","author":"Bartus R.T.","year":"2015","unstructured":"Bartus R.T.; Kordower J.H.; Johnson E.M.; Brown L.; Kruegel B.R.; Chu Y.; Baumann T.L.; Lang A.E.; Olanow C.W.; Herzog C.D.; Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies. Neurobiol Dis  2015,78,162-171","journal-title":"Neurobiol Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.nbd.2016.07.008","volume":"96","author":"Runeberg-Roos P.","year":"2016","unstructured":"Runeberg-Roos P.; Piccinini E.; Penttinen A.M.; M\u00e4tlik K.; Heikkinen H.; Kuure S.; Bespalov M.M.; Per\u00e4nen J.; Garea-Rodr\u00edguez E.; Fuchs E.; Airavaara M.; Kalkkinen N.; Penn R.; Saarma M.; Developing therapeutically more efficient Neurturin variants for treatment of Parkinson\u2019s disease. Neurobiol Dis  2016,96,335-345","journal-title":"Neurobiol Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1113\/JP271322","volume":"594","author":"Benedetti F.","year":"2016","unstructured":"Benedetti F.; Frisaldi E.; Carlino E.; Giudetti L.; Pampallona A.; Zibetti M.; Lanotte M.; Lopiano L.; Teaching neurons to respond to placebos. J Physiol  2016,594(19),5647-5660","journal-title":"J Physiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.expneurol.2012.02.012","volume":"235","author":"Decressac M.","year":"2012","unstructured":"Decressac M.; Mattsson B.; Bj\u00f6rklund A.; Comparison of the behavioural and histological characteristics of the 6-OHDA and \u03b1-synuclein rat models of Parkinson\u2019s disease. Exp Neurol  2012,235(1),306-315","journal-title":"Exp Neurol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.tins.2010.09.004","volume":"33","author":"Venda L.L.","year":"2010","unstructured":"Venda L.L.; Cragg S.J.; Buchman V.L.; Wade-Martins R.; \u03b1-Synuclein and dopamine at the crossroads of Parkinson\u2019s disease. Trends Neurosci  2010,33(12),559-568","journal-title":"Trends Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1093\/brain\/awr149","volume":"134","author":"Decressac M.","year":"2011","unstructured":"Decressac M.; Ulusoy A.; Mattsson B.; Georgievska B.; Romero-Ramos M.; Kirik D.; Bj\u00f6rklund A.; GDNF fails to exert neuroprotection in a rat -synuclein model of Parkinson\u2019s disease. Brain  2011,134(8),2302-2311","journal-title":"Brain"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1523\/JNEUROSCI.22-07-02780.2002","volume":"22","author":"Kirik D.","year":"2002","unstructured":"Kirik D.; Rosenblad C.; Burger C.; Lundberg C.; Johansen T.E.; Muzyczka N.; Mandel R.J.; Bj\u00f6rklund A.; Parkinson-like neurodegeneration induced by targeted overexpression of \u03b1-synuclein in the nigrostriatal system. J Neurosci  2002,22(7),2780-2791","journal-title":"J Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.pneurobio.2005.09.001","volume":"77","author":"Jankovic J.","year":"2005","unstructured":"Jankovic J.; Chen S.; Le W.D.; The role of Nurr1 in the development of dopaminergic neurons and Parkinson\u2019s disease. Prog Neurobiol  2005,77(1-2),128-138","journal-title":"Prog Neurobiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jns.2008.06.007","volume":"273","author":"Le W.","year":"2008","unstructured":"Le W.; Pan T.; Huang M.; Xu P.; Xie W.; Zhu W.; Zhang X.; Deng H.; Jankovic J.; Decreased NURR1 gene expression in patients with Parkinson\u2019s disease. J Neurol Sci  2008,273(1-2),29-33","journal-title":"J Neurol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"510","DOI":"10.15252\/emmm.201404610","volume":"7","author":"Oh S.M.","year":"2015","unstructured":"Oh S.M.; Chang M.Y.; Song J.J.; Rhee Y.H.; Joe E.H.; Lee H.S.; Yi S.H.; Lee S.H.; Combined Nurr1 and Foxa2 roles in the therapy of Parkinson\u2019s disease. EMBO Mol Med  2015,7(5),510-525","journal-title":"EMBO Mol Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/cns.12536","volume":"22","author":"Dong J.","year":"2016","unstructured":"Dong J.; Li S.; Mo J.L.; Cai H.B.; Le W.D.; Nurr1\u2010based therapies for Parkinson\u2019s disease. CNS Neurosci Ther  2016,22(5),351-359","journal-title":"CNS Neurosci Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.yexcr.2008.05.001","volume":"314","author":"Apostolou A.","year":"2008","unstructured":"Apostolou A.; Shen Y.; Liang Y.; Luo J.; Fang S.; Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp Cell Res  2008,314(13),2454-2467","journal-title":"Exp Cell Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"25893","DOI":"10.1074\/jbc.M112.356345","volume":"287","author":"Glembotski C.C.","year":"2012","unstructured":"Glembotski C.C.; Thuerauf D.J.; Huang C.; Vekich J.A.; Gottlieb R.A.; Doroudgar S.; Mesencephalic astrocyte-derived neurotrophic factor protects the heart from ischemic damage and is selectively secreted upon sarco\/endoplasmic reticulum calcium depletion. J Biol Chem  2012,287(31),25893-25904","journal-title":"J Biol Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e2032","DOI":"10.1038\/cddis.2015.371","volume":"6","author":"M\u00e4tlik K.","year":"2015","unstructured":"M\u00e4tlik K.; Yu L.; Eesmaa A.; Hellman M.; Lindholm P.; Per\u00e4nen J.; Galli E.; Anttila J.; Saarma M.; Permi P.; Airavaara M.; Arum\u00e4e U.; Role of two sequence motifs of mesencephalic astrocyte-derived neurotrophic factor in its survival-promoting activity. Cell Death Dis  2015,6(12),e2032","journal-title":"Cell Death Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.medidd.2023.100158","volume":"18","author":"Rajput S.","year":"2023","unstructured":"Rajput S.; Kumar Sharma P.; Malviya R.; Fluid mechanics in circulating tumour cells: Role in metastasis and treatment strategies. Med Drug Discov  2023,18,100158","journal-title":"Med Drug Discov"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.molmed.2012.12.005","volume":"19","author":"Mercado G.","year":"2013","unstructured":"Mercado G.; Vald\u00e9s P.; Hetz C.; An ERcentric view of Parkinson\u2019s disease. Trends Mol Med  2013,19(3),165-175","journal-title":"Trends Mol Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/JMN:20:2:173","volume":"20","author":"Petrova P.S.","year":"2003","unstructured":"Petrova P.S.; Raibekas A.; Pevsner J.; Vigo N.; Anafi M.; Moore M.K.; Peaire A.E.; Shridhar V.; Smith D.I.; Kelly J.; Durocher Y.; Commissiong J.W.; MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci  2003,20(2),173-188","journal-title":"J Mol Neurosci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nature05957","volume":"448","author":"Lindholm P.","year":"2007","unstructured":"Lindholm P.; Voutilainen M.H.; Laur\u00e9n J.; Per\u00e4nen J.; Lepp\u00e4nen V.M.; Andressoo J.O.; Lindahl M.; Janhunen S.; Kalkkinen N.; Timmusk T.; Tuominen R.K.; Saarma M.; Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature  2007,448(7149),73-77","journal-title":"Nature"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/brb3.117","volume":"3","author":"B\u00e4ck S.","year":"2013","unstructured":"B\u00e4ck S.; Per\u00e4nen J.; Galli E.; Pulkkila P.; Lonka-Nevalaita L.; Tamminen T.; Voutilainen M.H.; Raasmaja A.; Saarma M.; M\u00e4nnist\u00f6 P.T.; Tuominen R.K.; Gene therapy with AAV 2\u2010 CDNF provides functional benefits in a rat model of P arkinson\u2019s disease. Brain Behav  2013,3(2),75-88","journal-title":"Brain Behav"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.expneurol.2013.06.002","volume":"248","author":"Ren X.","year":"2013","unstructured":"Ren X.; Zhang T.; Gong X.; Hu G.; Ding W.; Wang X.; AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp Neurol  2013,248,148-156","journal-title":"Exp Neurol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/mt.2014.206","volume":"23","author":"Cordero-Llana \u00d3.","year":"2015","unstructured":"Cordero-Llana \u00d3.; Houghton B.C.; Rinaldi F.; Taylor H.; Y\u00e1\u00f1ez-Mu\u00f1oz R.J.; Uney J.B.; Wong L.F.; Caldwell M.A.; Enhanced efficacy of the CDNF\/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson\u2019s disease. Mol Ther  2015,23(2),244-254","journal-title":"Mol Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.expneurol.2017.01.008","volume":"291","author":"Hao F.","year":"2017","unstructured":"Hao F.; Yang C.; Chen S.S.; Wang Y.Y.; Zhou W.; Hao Q.; Lu T.; Hoffer B.; Zhao L.R.; Duan W.M.; Xu Q.Y.; Long-term protective effects of AAV9-mesencephalic astrocyte-derived neurotrophic factor gene transfer in parkinsonian rats. Exp Neurol  2017,291,120-133","journal-title":"Exp Neurol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0959-4388(00)00208-7","volume":"11","author":"Patapoutian A.","year":"2001","unstructured":"Patapoutian A.; Reichardt L.F.; Trk receptors: Mediators of neurotrophin action. Curr Opin Neurobiol  2001,11(3),272-280","journal-title":"Curr Opin Neurobiol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11064-011-0491-5","volume":"36","author":"Ding Y.X.","year":"2011","unstructured":"Ding Y.X.; Xia Y.; Jiao X.Y.; Duan L.; Yu J.; Wang X.; Chen L.W.; The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57\/BL mice. Neurochem Res  2011,36(10),1759-1766","journal-title":"Neurochem Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/350230a0","volume":"350","author":"Hyman C.","year":"1991","unstructured":"Hyman C.; Hofer M.; Barde Y.A.; Juhasz M.; Yancopoulos G.D.; Squinto S.P.; Lindsay R.M.; BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature  1991,350(6315),230-232","journal-title":"Nature"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.expneurol.2004.11.030","volume":"192","author":"Porritt M.J.","year":"2005","unstructured":"Porritt M.J.; Batchelor P.E.; Howells D.W.; Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol  2005,192(1),226-234","journal-title":"Exp Neurol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1227\/00006123-199510000-00018","volume":"37","author":"Tsukahara T.","year":"1995","unstructured":"Tsukahara T.; Takeda M.; Shimohama S.; Ohara O.; Hashimoto N.; Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mon-keys. Neurosurgery  1995,37(4),733-741","journal-title":"Neurosurgery"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.brainres.2005.05.072","volume":"1052","author":"Sun M.","year":"2005","unstructured":"Sun M.; Kong L.; Wang X.; Lu X.; Gao Q.; Geller A.I.; Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson\u2019s disease. Brain Res  2005,1052(2),119-129","journal-title":"Brain Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12929-015-0166-7","volume":"22","author":"Hernandez-Chan N.G.","year":"2015","unstructured":"Hernandez-Chan N.G.; Bannon M.J.; Orozco-Barrios C.E.; Escobedo L.; Zamudio S.; De la Cruz F.; Gongora-Alfaro J.L.; Armend\u00e1riz-Borunda J.; Reyes-Corona D.; Espadas-Alvarez A.J.; Flores-Mart\u00ednez Y.M.; Ayala-Davila J.; Hernandez-Gutierrez M.E.; Pav\u00f3n L.; Garc\u00eda-Villegas R.; Nadella R.; Martinez-Fong D.; Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson\u2019s disease. J Biomed Sci  2015,22(1),59","journal-title":"J Biomed Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/0306-4522(93)90612-J","volume":"53","author":"Lapchak P.A.","year":"1993","unstructured":"Lapchak P.A.; Beck K.D.; Araujo D.M.; Irwin I.; Langston J.W.; Hefti F.; Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection. Neuroscience  1993,53(3),639-650","journal-title":"Neuroscience"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"Ferrara N.","year":"2003","unstructured":"Ferrara N.; Gerber H.P.; LeCouter J.; The biology of VEGF and its receptors. Nat Med  2003,9(6),669-676","journal-title":"Nat Med"},{"key":"ref=69","first-page":"1029","volume":"146","author":"Dvorak H.F.","year":"1995","unstructured":"Dvorak H.F.; Brown L.F.; Detmar M.; Dvorak A.M.; Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol  1995,146(5),1029-1039","journal-title":"Am J Pathol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1050-1738(01)00140-2","volume":"12","author":"Neufeld G.","year":"2002","unstructured":"Neufeld G.; Cohen T.; Shraga N.; Lange T.; Kessler O.; Herzog Y.; The neuropilins: Multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med  2002,12(1),13-19","journal-title":"Trends Cardiovasc Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"Schrag A.","year":"2000","unstructured":"Schrag A.; Quinn N.; Dyskinesias and motor fluctuations in Parkinson\u2019s disease. Brain  2000,123(11),2297-2305","journal-title":"Brain"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archneur.56.5.529","volume":"56","author":"Fahn S.","year":"1999","unstructured":"Fahn S.; Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs. Later L-DOPA. Arch Neurol  1999,56(5),529-535","journal-title":"Arch Neurol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"Fahn S.","year":"2004","unstructured":"Fahn S.; Oakes D.; Shoulson I.; Kieburtz K.; Rudolph A.; Lang A.; Olanow C.W.; Tanner C.; Marek K.; Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med  2004,351(24),2498-2508","journal-title":"N Engl J Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"101405","DOI":"10.1016\/j.nanoso.2024.101405","volume":"40","author":"Rajput S.","year":"2024","unstructured":"Rajput S.; Malviya R.; Sridhar S.B.; Nanoparticle-based photodynamic therapy for targeted treatment of breast cancer. Nano-Structures and Nano-Objects  2024,40,101405","journal-title":"Nano-Structures and Nano-Objects"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"Rascol O.","year":"2000","unstructured":"Rascol O.; Brooks D.J.; Korczyn A.D.; De Deyn P.P.; Clarke C.E.; Lang A.E.; A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med  2000,342(20),1484-1491","journal-title":"N Engl J Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Pramipexole C.","year":"2000","unstructured":"Pramipexole C.; Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA  2000,284(15),1931-1938","journal-title":"JAMA"},{"key":"ref=77","first-page":"1044","volume":"61","author":"Holloway R.G.","year":"2004","unstructured":"Holloway R.G.; Shoulson I.; Fahn S.; Kieburtz K.; Lang A.; Marek K.; McDermott M.; Seibyl J.; Weiner W.; Musch B.; Kamp C.; Welsh M.; Shinaman A.; Pahwa R.; Barclay L.; Hubble J.; LeWitt P.; Miyasaki J.; Suchowersky O.; Stacy M.; Russell D.S.; Ford B.; Hammerstad J.; Riley D.; Standaert D.; Wooten F.; Factor S.; Jankovic J.; Atassi F.; Kurlan R.; Panisset M.; Rajput A.; Rodnitzky R.; Shults C.; Petsinger G.; Waters C.; Pfeiffer R.; Biglan K.; Borchert L.; Montgomery A.; Sutherland L.; Weeks C.; DeAngelis M.; Sime E.; Wood S.; Pantella C.; Harrigan M.; Fussell B.; Dillon S.; Alexander-Brown B.; Rainey P.; Tennis M.; Rost-Ruffner E.; Brown D.; Evans S.; Berry D.; Hall J.; Shirley T.; Dobson J.; Fontaine D.; Pfeiffer B.; Brocht A.; Bennett S.; Daigneault S.; Hodgeman K.; O\u2019Connell C.; Ross T.; Richard K.; Watts A.; Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol  2004,61(7),1044-1053","journal-title":"Arch Neurol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00002826-200305000-00001","volume":"26","author":"M\u00fcller T.","year":"2003","unstructured":"M\u00fcller T.; Fritze J.; Fibrosis associated with dopamine agonist therapy in Parkinson\u2019s disease. Clin Neuropharmacol  2003,26(3),109-111","journal-title":"Clin Neuropharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"Zanettini R.","year":"2007","unstructured":"Zanettini R.; Antonini A.; Gatto G.; Gentile R.; Tesei S.; Pezzoli G.; Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med  2007,356(1),39-46","journal-title":"N Engl J Med"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","volume":"66","author":"Voon V.","year":"2006","unstructured":"Voon V.; Hassan K.; Zurowski M.; Duff-Canning S.; de Souza M.; Fox S.; Lang A.E.; Miyasaki J.; Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology  2006,66(11),1750-1752","journal-title":"Neurology"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.parkreldis.2006.02.004","volume":"12","author":"Imamura A.","year":"2006","unstructured":"Imamura A.; Uitti R.J.; Wszolek Z.K.; Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord  2006,12(8),506-508","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1136\/bmj.311.7020.1602","volume":"311","author":"Lees A.J.","year":"1995","unstructured":"Lees A.J.; Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson\u2019s disease. BMJ  1995,311(7020),1602-1607","journal-title":"BMJ"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ana.410390107","volume":"39","author":"Group T.P.","year":"1996","unstructured":"Group T.P.; Impact of deprenyl and tocopherol treatment on Parkinson\u2019s disease in DATATOP patients requiring levodopa. Ann Neurol  1996,39(1),37-45","journal-title":"Ann Neurol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/bmj.38184.606169.AE","volume":"329","author":"Ives N.J.","year":"2004","unstructured":"Ives N.J.; Stowe R.L.; Marro J.; Counsell C.; Macleod A.; Clarke C.E.; Gray R.; Wheatley K.; Monoamine oxidase type B inhibitors in early Parkinson\u2019s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ  2004,329(7466),593","journal-title":"BMJ"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","year":"2002","unstructured":"A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol  2002,59(12),1937-1943","journal-title":"Arch Neurol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/mds.10508","volume":"18","author":"Mizuno Y.","year":"2003","unstructured":"Mizuno Y.; Yanagisawa N.; Kuno S.; Yamamoto M.; Hasegawa K.; Origasa H.; Kowa H.; Randomized, double\u2010blind study of pramipexole with placebo and bromocriptine in advanced Parkinson\u2019s disease. Mov Disord  2003,18(10),1149-1156","journal-title":"Mov Disord"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s007020200040","volume":"109","author":"Brunt E.R.","year":"2002","unstructured":"Brunt E.R.; Brooks D.J.; Korczyn A.D.; Montastruc J.L.; Stocchi F.; A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson\u2019s disease not optimally controlled by L-dopa. J Neural Transm (Vienna)  2002,109(4),489-501","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"Metman L.V.","year":"1998","unstructured":"Metman L.V.; Del Dotto P.; van den Munckhof P.; Fang J.; Mouradian M.M.; Chase T.N.; Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology  1998,50(5),1323-1326","journal-title":"Neurology"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873:AID-MDS1017>3.0.CO;2-I","volume":"15","author":"Luginger E.","year":"2000","unstructured":"Luginger E.; Wenning G.K.; B\u00f6sch S.; Poewe W.; Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord  2000,15(5),873-878","journal-title":"Mov Disord"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/bmb\/ldn013","volume":"86","author":"Davie C.A.","year":"2008","unstructured":"Davie C.A.; A review of Parkinson\u2019s disease. Br Med Bull  2008,86(1),109-127","journal-title":"Br Med Bull"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/1531-8257(200009)15:5<789:AID-MDS1005>3.0.CO;2-H","volume":"15","author":"Poewe W.","year":"2000","unstructured":"Poewe W.; Wenning G.K.; Apomorphine: An underutilized therapy for Parkinson\u2019s disease. Mov Disord  2000,15(5),789-794","journal-title":"Mov Disord"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"Nyholm D.","year":"2005","unstructured":"Nyholm D.; Nilsson Remahl A.I.M.; Dizdar N.; Constantinescu R.; Holmberg B.; Jansson R.; Aquilonius S.M.; Askmark H.; Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology  2005,64(2),216-223","journal-title":"Neurology"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/jgm.1361","volume":"11","author":"Huang R.","year":"2009","unstructured":"Huang R.; Han L.; Li J.; Ren F.; Ke W.; Jiang C.; Pei Y.; Neuroprotection in a 6\u2010hydroxydopamine\u2010lesioned Parkinson model using lactoferrin\u2010modified nanoparticles. J Gene Med  2009,11,754-763","journal-title":"J Gene Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.ymthe.2006.09.001","volume":"14","author":"Gonzalez-Barrios J.A.","year":"2006","unstructured":"Gonzalez-Barrios J.A.; Lindahl M.; Bannon M.J.; Anaya-Mart\u00ednez V.; Flores G.; Navarro-Quiroga I.; Trudeau L.E.; Aceves J.; Martinez-Arguelles D.B.; Garcia-Villegas R.; Jim\u00e9nez I.; Segovia J.; Martinez-Fong D.; Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther  2006,14(6),857-865","journal-title":"Mol Ther"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1566523223666230731093030","volume":"24","author":"Sundram S.","year":"2024","unstructured":"Sundram S.; Dhiman N.; Malviya R.; Awasth R.; Non-coding RNAs in regulation of protein aggregation and clearance pathways: Current perspectives towards Alzheimer\u2019s research and therapy. Curr Gene Ther  2024,24(1),8-16","journal-title":"Curr Gene Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"10302","DOI":"10.1523\/JNEUROSCI.22-23-10302.2002","volume":"22","author":"Azzouz M.","year":"2002","unstructured":"Azzouz M.; Martin-Rendon E.; Barber R.D.; Mitrophanous K.A.; Carter E.E.; Rohll J.B.; Kingsman S.M.; Kingsman A.J.; Mazarakis N.D.; Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson\u2019s disease. J Neurosci  2002,22(23),10302-10312","journal-title":"J Neurosci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2ra4","DOI":"10.1126\/scitranslmed.3000130","volume":"1","author":"Jarraya B.","year":"2009","unstructured":"Jarraya B.; Boulet S.; Scott Ralph G.; Jan C.; Bonvento G.; Azzouz M.; Miskin J.E.; Shin M.; Delzescaux T.; Drouot X.; H\u00e9rard A.S.; Day D.M.; Brouillet E.; Kingsman S.M.; Hantraye P.; Mitrophanous K.A.; Mazarakis N.D.; Palfi S.; Dopamine gene therapy for Parkinson\u2019s disease in a nonhuman primate without associated dyskinesia. Sci Transl Med  2009,1(2),2ra4","journal-title":"Sci Transl Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2174\/1570159X22666240530105516","volume":"23","author":"Azman K.F.","year":"2025","unstructured":"Azman K.F.; Zakaria R.; Brain-derived neurotrophic factor (BDNF) in Huntington\u2019s disease: Neurobiology and therapeutic potential. Curr Neuropharmacol  2025,23(4),384-403","journal-title":"Curr Neuropharmacol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0006-8993(99)02116-2","volume":"847","author":"Klein R.L.","year":"1999","unstructured":"Klein R.L.; Lewis M.H.; Muzyczka N.; Meyer E.M.; Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res  1999,847(2),314-320","journal-title":"Brain Res"},{"key":"ref=100","author":"Batts A.J.","year":"2025","unstructured":"Batts A.J.; Ji R.; Bae S.; Tsitsos F.N.; Jim\u00e9nez-Gamb\u00edn S.; Kwon N.; Gorman S.L.; Tsakri D.; Noel R.L.; Bendig J.; Jimenez D.A.; Portable transcranial therapeutic ultrasound enhances targeted gene delivery for Parkinson\u2019s disease: From rodent models to non-human primates. BioRxiv  2025","journal-title":"BioRxiv"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jchemneu.2009.06.010","volume":"38","author":"Kitahama K.","year":"2009","unstructured":"Kitahama K.; Ikemoto K.; Jouvet A.; Araneda S.; Nagatsu I.; Raynaud B.; Nishimura A.; Nishi K.; Niwa S.; Aromatic l-amino acid decarboxylase-immunoreactive structures in human midbrain, pons, and medulla. J Chem Neuroanat  2009,38(2),130-140","journal-title":"J Chem Neuroanat"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ymthe.2006.05.005","volume":"14","author":"Bankiewicz K.S.","year":"2006","unstructured":"Bankiewicz K.S.; Forsayeth J.; Eberling J.L.; Sanchez-Pernaute R.; Pivirotto P.; Bringas J.; Herscovitch P.; Carson R.E.; Eckelman W.; Reutter B.; Cunningham J.; Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther  2006,14(4),564-570","journal-title":"Mol Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/mt.2010.106","volume":"18","author":"Hadaczek P.","year":"2010","unstructured":"Hadaczek P.; Eberling J.L.; Pivirotto P.; Bringas J.; Forsayeth J.; Bankiewicz K.S.; Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther  2010,18(8),1458-1461","journal-title":"Mol Ther"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"Christine C.W.","year":"2009","unstructured":"Christine C.W.; Starr P.A.; Larson P.S.; Eberling J.L.; Jagust W.J.; Hawkins R.A.; VanBrocklin H.F.; Wright J.F.; Bankiewicz K.S.; Aminoff M.J.; Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology  2009,73(20),1662-1669","journal-title":"Neurology"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.ymthe.2025.03.030","volume":"33","author":"Szunyogh S.","year":"2025","unstructured":"Szunyogh S.; Carroll E.; Wade-Martins R.; Recent developments in gene therapy for Parkinson\u2019s disease. Mol Ther  2025,33(5),2052-2064","journal-title":"Mol Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/d41573-023-00192-9","volume":"23","author":"Kingwell K.","year":"2024","unstructured":"Kingwell K.; Gene therapy zeroes in on Parkinson disease brain circuits. Nat Rev Drug Discov  2024,23(1),20","journal-title":"Nat Rev Drug Discov"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1073\/pnas.89.6.2115","volume":"89","author":"Bu D.F.","year":"1992","unstructured":"Bu D.F.; Erlander M.G.; Hitz B.C.; Tillakaratne N.J.; Kaufman D.L.; Wagner-McPherson C.B.; Evans G.A.; Tobin A.J.; Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci USA  1992,89(6),2115-2119","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0896-6273(91)90077-D","volume":"7","author":"Erlander M.G.","year":"1991","unstructured":"Erlander M.G.; Tillakaratne N.J.K.; Feldblum S.; Patel N.; Tobin A.J.; Two genes encode distinct glutamate decarboxylases. Neuron  1991,7(1),91-100","journal-title":"Neuron"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.2174\/0115680266366494250411164750","volume":"25","author":"Rana A.","year":"2025","unstructured":"Rana A.; Mittal A.; Vashist C.; Rajput S.; Sridhar S.B.; Sharma S.; Malviya R.; Advancements in herbal drug loaded nanoparticulate system for antimicrobial effect. Curr Top Med Chem  2025,25(25),2918-2936","journal-title":"Curr Top Med Chem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(SICI)1097-4547(19990701)57:1<137:AID-JNR15>3.0.CO;2-D","volume":"57","author":"Mi J.","year":"1999","unstructured":"Mi J.; Chatterjee S.; Wong K.K.; Forbes C.; Lawless G.; Tobin A.J.; Recombinant adeno-associated virus (AAV) drives constitutive production of glutamate decarboxylase in neural cell lines. J Neurosci Res  1999,57(1),137-148","journal-title":"J Neurosci Res"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1074549","volume":"298","author":"Luo J.","year":"2002","unstructured":"Luo J.; Kaplitt M.G.; Fitzsimons H.L.; Zuzga D.S.; Liu Y.; Oshinsky M.L.; During M.J.; Subthalamic GAD gene therapy in a Parkinson\u2019s disease rat model. Science  2002,298(5592),425-429","journal-title":"Science"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/sj.gt.3302520","volume":"12","author":"Lee B.","year":"2005","unstructured":"Lee B.; Lee H.; Nam Y.R.; Oh J.H.; Cho Y.H.; Chang J.W.; Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Ther  2005,12(15),1215-1222","journal-title":"Gene Ther"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.jcbfm.9600364","volume":"27","author":"Emborg M.E.","year":"2007","unstructured":"Emborg M.E.; Carbon M.; Holden J.E.; During M.J.; Ma Y.; Tang C.; Moirano J.; Fitzsimons H.; Roitberg B.Z.; Tuccar E.; Roberts A.; Kaplitt M.G.; Eidelberg D.; Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab  2007,27(3),501-509","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"Kaplitt M.G.","year":"2007","unstructured":"Kaplitt M.G.; Feigin A.; Tang C.; Fitzsimons H.L.; Mattis P.; Lawlor P.A.; Bland R.J.; Young D.; Strybing K.; Eidelberg D.; During M.J.; Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet  2007,369(9579),2097-2105","journal-title":"Lancet"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"LeWitt P.A.","year":"2011","unstructured":"LeWitt P.A.; Rezai A.R.; Leehey M.A.; Ojemann S.G.; Flaherty A.W.; Eskandar E.N.; Kostyk S.K.; Thomas K.; Sarkar A.; Siddiqui M.S.; Tatter S.B.; Schwalb J.M.; Poston K.L.; Henderson J.M.; Kurlan R.M.; Richard I.H.; Van Meter L.; Sapan C.V.; During M.J.; Kaplitt M.G.; Feigin A.; AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol  2011,10(4),309-319","journal-title":"Lancet Neurol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S1474-4422(10)70256-8","volume":"9","author":"Benabid A.L.","year":"2010","unstructured":"Benabid A.L.; Gene therapy for Parkinson\u2019s disease: Do we have the cure? Lancet Neurol  2010,9(12),1142-1143","journal-title":"Lancet Neurol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0022-3565(25)30363-0","volume":"195","author":"Lloyd K.G.","year":"1975","unstructured":"Lloyd K.G.; Davidson L.; Hornykiewicz O.; The neurochemistry of Parkinson\u2019s disease: effect of L-dopa therapy. J Pharmacol Exp Ther  1975,195(3),453-464","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=118","author":"Nagatsu T.","year":"2007","unstructured":"Nagatsu T.; Sawada M.;  Biochemistry of postmortem brains in Parkinson\u2019s disease: Historical overview and future prospects  2007","journal-title":"Biochemistry of postmortem brains in Parkinson\u2019s disease: Historical overview and future prospects"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1056\/NEJM199810153391607","volume":"339","author":"Lang A.E.","year":"1998","unstructured":"Lang A.E.; Lozano A.M.; Parkinson\u2019s disease. N Engl J Med  1998,339(16),1130-1143","journal-title":"N Engl J Med"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0306-4522(98)00741-6","volume":"92","author":"Leff S.E.","year":"1999","unstructured":"Leff S.E.; Spratt S.K.; Snyder R.O.; Mandel R.J.; Long-term restoration of striatal l-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson\u2019s disease. Neuroscience  1999,92(1),185-196","journal-title":"Neuroscience"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1006\/exnr.2000.7408","volume":"164","author":"Bankiewicz K.S.","year":"2000","unstructured":"Bankiewicz K.S.; Eberling J.L.; Kohutnicka M.; Jagust W.; Pivirotto P.; Bringas J.; Cunningham J.; Budinger T.F.; Harvey-White J.; Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol  2000,164(1),2-14","journal-title":"Exp Neurol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1007\/s10072-024-07599-1","volume":"45","author":"Grote J.","year":"2024","unstructured":"Grote J.; Patel N.; Bates C.; Parmar M.S.; From lab bench to hope: A review of gene therapies in clinical trials for Parkinson\u2019s disease and challenges. Neurol Sci  2024,45(10),4699-4710","journal-title":"Neurol Sci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/384467a0","volume":"384","author":"Kotzbauer P.T.","year":"1996","unstructured":"Kotzbauer P.T.; Lampe P.A.; Heuckeroth R.O.; Golden J.P.; Creedon D.J.; Johnson E.M.; Milbrandt J.; Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature  1996,384(6608),467-470","journal-title":"Nature"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1523\/JNEUROSCI.18-13-04929.1998","volume":"18","author":"Horger B.A.","year":"1998","unstructured":"Horger B.A.; Nishimura M.C.; Armanini M.P.; Wang L.C.; Poulsen K.T.; Rosenblad C.; Kirik D.; Moffat B.; Simmons L.; Johnson E.; Milbrandt J.; Rosenthal A.; Bjorklund A.; Vandlen R.A.; Hynes M.A.; Phillips H.S.; Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci  1998,18(13),4929-4937","journal-title":"J Neurosci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1097\/00001756-199806010-00027","volume":"9","author":"Tseng J.L.","year":"1998","unstructured":"Tseng J.L.; Bruhn S.L.; Zurn A.D.; Aebischer P.; Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy. Neuroreport  1998,9(8),1817-1822","journal-title":"Neuroreport"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0006-8993(02)02934-7","volume":"947","author":"Oiwa Y.","year":"2002","unstructured":"Oiwa Y.; Yoshimura R.; Nakai K.; Itakura T.; Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson\u2019s disease. Brain Res  2002,947(2),271-283","journal-title":"Brain Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/sj.mt.6300010","volume":"15","author":"Gasmi M.","year":"2007","unstructured":"Gasmi M.; Herzog C.D.; Brandon E.P.; Cunningham J.J.; Ramirez G.A.; Ketchum E.T.; Bartus R.T.; Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson\u2019s disease. Mol Ther  2007,15(1),62-68","journal-title":"Mol Ther"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40263-025-01203-6","volume":"39","author":"Phielipp N.","year":"2025","unstructured":"Phielipp N.; Henchcliffe C.; Investigational gene therapies for parkinson\u2019s disease. CNS Drugs  2025,39(8),725-737","journal-title":"CNS Drugs"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.3390\/ijms252212369","volume":"25","author":"Kim J.","year":"2024","unstructured":"Kim J.; Chang M.Y.; Gene therapy for Parkinson\u2019s disease using midbrain developmental genes to regulate dopaminergic neuronal maintenance. Int J Mol Sci  2024,25(22),12369","journal-title":"Int J Mol Sci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/brain\/awh029","volume":"127","author":"Hamani C.","year":"2004","unstructured":"Hamani C.; Saint-Cyr J.A.; Fraser J.; Kaplitt M.; Lozano A.M.; The subthalamic nucleus in the context of movement disorders. Brain  2004,127(1),4-20","journal-title":"Brain"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S1474-4422(25)00125-5","volume":"24","author":"Winston G.","year":"2025","unstructured":"Winston G.; Kharas N.; Svenningsson P.; Jha A.; Kaplitt M.G.; Gene therapy for Parkinson\u2019s disease: trials and technical advances. Lancet Neurol  2025,24(6),548-556","journal-title":"Lancet Neurol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/0115665232283842240102073002","volume":"24","author":"Tripathi R.K.","year":"2024","unstructured":"Tripathi R.K.; Goyal L.; Singh S.; Potential therapeutic approach using aromatic l-amino acid decarboxylase and glial-derived neurotrophic factor therapy targeting putamen in parkinson\u2019s disease. Curr Gene Ther  2024,24(4),278-291","journal-title":"Curr Gene Ther"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"e67037","DOI":"10.7759\/cureus.67037","volume":"16","author":"Roberts W.S.","year":"2024","unstructured":"Roberts W.S.; Price S.; Wu M.; Parmar M.S.; Emerging gene therapies for Alzheimer\u2019s and Parkinson\u2019s diseases: an overview of clinical trials and promising candidates. Cureus  2024,16(8),e67037","journal-title":"Cureus"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S1474-4422(07)70202-8","volume":"6","author":"Svendsen C.","year":"2007","unstructured":"Svendsen C.; The first steps towards gene therapy for Parkinson\u2019s disease. Lancet Neurol  2007,6(9),754-756","journal-title":"Lancet Neurol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1007\/s12035-024-04008-8","volume":"61","author":"dos Santos J.C.C.","year":"2024","unstructured":"dos Santos J.C.C.; Mano G.B.C.; da Cunha Barreto-Vianna A.R.; Garcia T.F.M.; de Vasconcelos A.V.; S\u00e1 C.S.G.; de Souza Santana S.L.; Farias A.G.P.; Seimaru B.; Lima M.P.P.; Goes J.V.C.; Gusm\u00e3o C.T.P.; Junior H.L.R.; The molecular impact of glucosylceramidase Beta 1 (Gba1) in Parkinson\u2019s disease: A new genetic state of the art. Mol Neurobiol  2024,61(9),6754-6770","journal-title":"Mol Neurobiol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"7961","DOI":"10.21037\/qims-23-267","volume":"13","author":"Yan Y.","year":"2023","unstructured":"Yan Y.; Wang Z.; Wei W.; Yang Z.; Guo L.; Wang Z.; Wei X.; Correlation of brain iron deposition and freezing of gait in Parkinson\u2019s disease: A cross-sectional study. Quant Imaging Med Surg  2023,13(12),7961-7972","journal-title":"Quant Imaging Med Surg"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"S209","DOI":"10.3233\/JPD-212674","volume":"11","author":"Bj\u00f6rklund T.","year":"2021","unstructured":"Bj\u00f6rklund T.; Davidsson M.; Next-generation gene therapy for Parkinson\u2019s disease using engineered viral vectors. J Parkinsons Dis  2021,11(s2),S209-S217","journal-title":"J Parkinsons Dis"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1126\/science.aar5683","volume":"360","author":"Alessi D.R.","year":"2018","unstructured":"Alessi D.R.; Sammler E.; LRRK2 kinase in Parkinson\u2019s disease. Science  2018,360(6384),36-37","journal-title":"Science"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s13760-020-01473-5","volume":"120","author":"Cherian A.","year":"2020","unstructured":"Cherian A.; Divya K.P.; Genetics of Parkinson\u2019s disease. Acta Neurol Belg  2020,120(6),1297-1305","journal-title":"Acta Neurol Belg"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ajhg.2011.06.001","volume":"89","author":"Vilari\u00f1o-G\u00fcell C.","year":"2011","unstructured":"Vilari\u00f1o-G\u00fcell C.; Wider C.; Ross O.A.; Dachsel J.C.; Kachergus J.M.; Lincoln S.J.; Soto-Ortolaza A.I.; Cobb S.A.; Wilhoite G.J.; Bacon J.A.; Behrouz B.; Melrose H.L.; Hentati E.; Puschmann A.; Evans D.M.; Conibear E.; Wasserman W.W.; Aasly J.O.; Burkhard P.R.; Djaldetti R.; Ghika J.; Hentati F.; Krygowska-Wajs A.; Lynch T.; Melamed E.; Rajput A.; Rajput A.H.; Solida A.; Wu R.M.; Uitti R.J.; Wszolek Z.K.; Vingerhoets F.; Farrer M.J.; VPS35 mutations in Parkinson disease. Am J Hum Genet  2011,89(1),162-167","journal-title":"Am J Hum Genet"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1073\/pnas.0501282102","volume":"102","author":"Kim R.H.","year":"2005","unstructured":"Kim R.H.; Smith P.D.; Aleyasin H.; Hayley S.; Mount M.P.; Pownall S.; Wakeham A.; You-Ten A.J.; Kalia S.K.; Horne P.; Westaway D.; Lozano A.M.; Anisman H.; Park D.S.; Mak T.W.; Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA  2005,102(14),5215-5220","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/mds.26243","volume":"30","author":"Park J.S.","year":"2015","unstructured":"Park J.S.; Blair N.F.; Sue C.M.; The role of ATP13A2 in Parkinson\u2019s disease: Clinical phenotypes and molecular mechanisms. Mov Disord  2015,30(6),770-779","journal-title":"Mov Disord"},{"key":"ref=143","author":"Meglio M.","year":"2025","unstructured":"Meglio M.; Gene therapy AAV-GAD Gains regenerative medicine advanced therapy designation as potential Parkinson treatment. Gene Ther  2025","journal-title":"Gene Ther"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3233\/JPD-202004","volume":"10","author":"Barker R.A.","year":"2020","unstructured":"Barker R.A.; Bj\u00f6rklund A.; Gash D.M.; Whone A.; Van Laar A.; Kordower J.H.; Bankiewicz K.; Kieburtz K.; Saarma M.; Booms S.; Huttunen H.J.; Kells A.P.; Fiandaca M.S.; Stoessl A.J.; Eidelberg D.; Federoff H.; Voutilainen M.H.; Dexter D.T.; Eberling J.; Brundin P.; Isaacs L.; Mursaleen L.; Bresolin E.; Carroll C.; Coles A.; Fiske B.; Matthews H.; Lungu C.; Wyse R.K.; Stott S.; Lang A.E.; GDNF and Parkinson\u2019s disease: Where next? A summary from a recent workshop. J Parkinsons Dis  2020,10(3),875-891","journal-title":"J Parkinsons Dis"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575405524251008112752","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/247265\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575405524251008112752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:05:29Z","timestamp":1781064329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/247265\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":144,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575405524251008112752","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}